MetaCap

Apyx Medical Corporation (APYX)

NASDAQ: APYXHealth CareMedical/Dental InstrumentsUSD

2.40+0.01 (+0.42%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

APYX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$101.10M
EPS (TTM)
-$0.19
52-week range
2.25 – 5.08
Day range
2.35 – 2.46
Volume / Avg
100.12K / 146.81K
Beta
—

52-week range

$2.25$5.08

APYX stock today

Apyx Medical (APYX) closed at $2.40 on Nov 20, up 0.42% (+$0.01), versus the S&P 500's 3.70% decline. At this level, APYX sits near the bottom of its 52-week range of $2.25 to $5.08: 52.8% below the high, set on Jun 9, 2026 and 6.7% above the low. APYX is down 31.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.0%.

Apyx Medical has posted a net loss over the last twelve months (EPS of -$0.19), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Apyx Medical

Company profile

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures.

Industry
Medical/Dental Instruments
CEO
Mr. Charles D. Goodwin II
Headquarters
Clearwater, FL
Employees
205

Financial highlights

Full financials

In fiscal 2025, Apyx Medical generated $52.8 million in revenue, up 9.9% from fiscal 2024. Apyx Medical reported a net loss of $11.2 million, compared with a loss of $23.5 million a year earlier. Gross margin was 62.5% (up from 61.0%) and operating margin -12.2%.

Apyx Medical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$52.84M$48.10M$52.35M$44.51M$48.52M
Growth+9.86%-8.11%+17.61%-8.26%+75.08%
Net income$-11.21M$-23.46M$-18.71M$-23.18M$-15.17M
EPS (diluted)——$-0.54$-0.67$-0.44

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$6.50+170.83%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.04 vs $-0.07
Surprise
+42.86%

APYX news

All APYX news

Apyx Medical peers

Health Care sector
APYX peer companies
CompanyPrice% ChgMarket capCompare
LUNGPulmonx Corporation2.57-6.20%$111.93Mvs APYX
NYXHNyxoah SA0.805-7.01%$81.98Mvs APYX
STIMNeuronetics Inc.1.25+0.81%$120.60Mvs APYX
SKINSkinHealth Systems Inc. Class A11.77-3.13%$76.68Mvs APYX
LUCDLucid Diagnostics Inc.0.3727-3.52%$72.57Mvs APYX
PYPDPolyPid Ltd.6.12-6.56%$129.29Mvs APYX
QTEXQTREX Quantum Ltd.1.00-10.71%$70.63Mvs APYX
KRMDKORU Medical Systems Inc.3.19-7.27%$138.37Mvs APYX

Indexes, lists and sector

Apyx Medical stock FAQ

What is Apyx Medical's stock price today?

APYX last traded at $2.40 as of Nov 20, 4:00 PM EST, up 0.42% on the day. Prices are delayed at least 15 minutes.

Who is Apyx Medical's CEO?

Mr. Charles D. Goodwin II is the chief executive officer of Apyx Medical Corporation, which has about 205 employees.

What is the APYX 52-week high?

The 52-week high for APYX is $5.08 and the 52-week low is $2.25. The stock is currently 52.8% below its high.

Compare APYX